Cargando…
Comprehensive description of adult-onset Still's disease after COVID-19 vaccination
Cases of adult-onset Still's disease (AOSD) have been reported after COVID-19 vaccination. Here we provide a comprehensive description and analysis of all cases of AOSD reported in the literature and in pharmacovigilance databases through April 2022. Disproportionality analyses of pharmacovigil...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755011/ https://www.ncbi.nlm.nih.gov/pubmed/36592513 http://dx.doi.org/10.1016/j.jaut.2022.102980 |
_version_ | 1784851333458690048 |
---|---|
author | Palassin, Pascale Bres, Virginie Hassan, Samaher Alfonsi, Ange Massy, Nathalie Gras-Champel, Valérie Maria, Alexandre Thibault Jacques Faillie, Jean-Luc |
author_facet | Palassin, Pascale Bres, Virginie Hassan, Samaher Alfonsi, Ange Massy, Nathalie Gras-Champel, Valérie Maria, Alexandre Thibault Jacques Faillie, Jean-Luc |
author_sort | Palassin, Pascale |
collection | PubMed |
description | Cases of adult-onset Still's disease (AOSD) have been reported after COVID-19 vaccination. Here we provide a comprehensive description and analysis of all cases of AOSD reported in the literature and in pharmacovigilance databases through April 2022. Disproportionality analyses of pharmacovigilance data were performed in order to further explore the association between vaccination and AOSD. We included 159 patients, 144 from the World Health Organization pharmacovigilance database and 15 from the literature. Detailed clinical characteristics were described for the cases from the literature and from the French pharmacovigilance database (n = 9). The cases of AOSD after COVID-19 vaccination concerned women in 52.2% of cases. The median age was 43.4 years. More than 80% of AOSD reports occurred during the first three weeks and concerned mostly the BNT162b2 mRNA vaccine. We identified 14.5% of disease flare with a median time-to-onset of AOSD flare-up significantly shorter than for the new onset form. More than 90% patients received steroids. Although all cases were considered serious and required hospitalization, most cases presented a favorable outcome (67.1%) with a good response to corticosteroid therapy with a mean time to recovery of 7.2 days. Disproportionality analyses suggested that AOSD was associated with COVID-19 vaccines as well as other vaccines. AOSD was nearly five times more frequently reported with COVID-19 vaccines than with all other drugs. Clinicians should be informed about the potential risk of AOSD onset or flare following COVID vaccines and the importance of its early detection to optimize its management. |
format | Online Article Text |
id | pubmed-9755011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97550112022-12-16 Comprehensive description of adult-onset Still's disease after COVID-19 vaccination Palassin, Pascale Bres, Virginie Hassan, Samaher Alfonsi, Ange Massy, Nathalie Gras-Champel, Valérie Maria, Alexandre Thibault Jacques Faillie, Jean-Luc J Autoimmun Article Cases of adult-onset Still's disease (AOSD) have been reported after COVID-19 vaccination. Here we provide a comprehensive description and analysis of all cases of AOSD reported in the literature and in pharmacovigilance databases through April 2022. Disproportionality analyses of pharmacovigilance data were performed in order to further explore the association between vaccination and AOSD. We included 159 patients, 144 from the World Health Organization pharmacovigilance database and 15 from the literature. Detailed clinical characteristics were described for the cases from the literature and from the French pharmacovigilance database (n = 9). The cases of AOSD after COVID-19 vaccination concerned women in 52.2% of cases. The median age was 43.4 years. More than 80% of AOSD reports occurred during the first three weeks and concerned mostly the BNT162b2 mRNA vaccine. We identified 14.5% of disease flare with a median time-to-onset of AOSD flare-up significantly shorter than for the new onset form. More than 90% patients received steroids. Although all cases were considered serious and required hospitalization, most cases presented a favorable outcome (67.1%) with a good response to corticosteroid therapy with a mean time to recovery of 7.2 days. Disproportionality analyses suggested that AOSD was associated with COVID-19 vaccines as well as other vaccines. AOSD was nearly five times more frequently reported with COVID-19 vaccines than with all other drugs. Clinicians should be informed about the potential risk of AOSD onset or flare following COVID vaccines and the importance of its early detection to optimize its management. Elsevier Ltd. 2023-01 2022-12-16 /pmc/articles/PMC9755011/ /pubmed/36592513 http://dx.doi.org/10.1016/j.jaut.2022.102980 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Palassin, Pascale Bres, Virginie Hassan, Samaher Alfonsi, Ange Massy, Nathalie Gras-Champel, Valérie Maria, Alexandre Thibault Jacques Faillie, Jean-Luc Comprehensive description of adult-onset Still's disease after COVID-19 vaccination |
title | Comprehensive description of adult-onset Still's disease after COVID-19 vaccination |
title_full | Comprehensive description of adult-onset Still's disease after COVID-19 vaccination |
title_fullStr | Comprehensive description of adult-onset Still's disease after COVID-19 vaccination |
title_full_unstemmed | Comprehensive description of adult-onset Still's disease after COVID-19 vaccination |
title_short | Comprehensive description of adult-onset Still's disease after COVID-19 vaccination |
title_sort | comprehensive description of adult-onset still's disease after covid-19 vaccination |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755011/ https://www.ncbi.nlm.nih.gov/pubmed/36592513 http://dx.doi.org/10.1016/j.jaut.2022.102980 |
work_keys_str_mv | AT palassinpascale comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination AT bresvirginie comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination AT hassansamaher comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination AT alfonsiange comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination AT massynathalie comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination AT graschampelvalerie comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination AT mariaalexandrethibaultjacques comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination AT failliejeanluc comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination AT comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination |